New drugs; rimonabant;Nieuwe geneesmiddelen; rimonabant

Nederlands Tijdschrift voor Geneeskunde

Volumn 151, Issue 47, 2007, Pages 2620-2622

  Van Bronswijk, H ^a,b   Dubois, E A ^a   Pijl, H ^c,d   Cohen, A F ^a  

^a Leids Universitair Medisch Centrum ^*

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Centre for Human Drug Research   (Netherlands)

^d CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ENDOCANNABINOID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; PLACEBO; RIMONABANT; TRIACYLGLYCEROL;

ADIPOSE TISSUE; APPETITE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DRUG APPROVAL; DRUG MECHANISM; FOLLOW UP; FOOD INTAKE; HUMAN; HYPERLIPIDEMIA; LIFESTYLE MODIFICATION; LIPOGENESIS; MAJOR DEPRESSION; MENTAL DISEASE; NEUROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT CONTRAINDICATION;

APPETITE REGULATION; CARDIOVASCULAR DISEASES; DEPRESSION; DIET, REDUCING; ENERGY INTAKE; HUMANS; LIPIDS; LIPOGENESIS; OBESITY; OBESITY, MORBID; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; WEIGHT LOSS;

EID: 36749100995     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (8)

1. Gaal LF van, Rissanen AM, Scheen AJ, Ziegler O, Rössner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. RIO-Europe Study Group. Lancet. 2005;365:1389-97.
2. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. RIO-North America Study Group. JAMA. 2006;295:761-75.
3. Després JP, Golay A, Sjöström L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. Rimonabant in Obesity-Lipids Study Group. N Engl J Med. 2005;353:2121-34.
4. Scheen AJ, Finer N, Hollander P, Jensen MD, Gaal LF van. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. RIO-Diabetes Study Group. Lancet. 2006;368:1660-72.
5. Cahill K, Ussher M. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation [Cochrane review]. Cochrane Database Syst Rev. 2007;(3):CD005353.
6. Di Marzo V, Bifulco M, de Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov. 2004;3:771-84.
7. Maresz K, Pryce G, Ponomarev ED, Marsicano G, Croxford JL, Shriver LP, et al. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med. 2007;13:492-7.
8. Underdown NJ, Hiley CR, Ford WR. Anandamide reduces infarct size in rat isolated hearts subjected to ischaemia-reperfusion by a novel cannabinoid mechanism. Br J Pharmacol. 2005;146:809-16.